Literature DB >> 3037552

Anti-glycoprotein D antibodies that permit adsorption but block infection by herpes simplex virus 1 prevent virion-cell fusion at the cell surface.

A O Fuller, P G Spear.   

Abstract

Certain monoclonal antibodies specific for glycoprotein D of herpes simplex virus have potent neutralizing activity but fail to block attachment of virus to cells. Here we have investigated the fate of neutralized and infectious virus after attachment to primate cells. Infectious virions fused with the cell surface such that naked nucleocapsids were detectable in the cytoplasm near or just under the plasma membrane. Neutralized virions did not fuse with the cell. They remained attached to the cell surface and could be rendered infectious by treatment with polyethylene glycol. We conclude that some anti-glycoprotein D neutralizing antibodies can inhibit the penetration of herpes simplex virus by blocking fusion of the virion envelope with the plasma membrane. These results identify a pathway of entry that initiates successful herpes simplex virus infection and a step in this pathway that is highly sensitive to neutralizing antibodies. A role for glycoprotein D in virion-cell fusion is indicated.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3037552      PMCID: PMC298876          DOI: 10.1073/pnas.84.15.5454

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  29 in total

1.  Membrane proteins specified by herpes simplex viruses. III. Role of glycoprotein VP7(B2) in virion infectivity.

Authors:  M Sarmiento; M Haffey; P G Spear
Journal:  J Virol       Date:  1979-03       Impact factor: 5.103

2.  Cell fusion induced by herpes simplex virus is promoted and suppressed by different viral glycoproteins.

Authors:  R Manservigi; P G Spear; A Buchan
Journal:  Proc Natl Acad Sci U S A       Date:  1977-09       Impact factor: 11.205

3.  Role of the coated endocytic vesicle in the uptake of receptor-bound low density lipoprotein in human fibroblasts.

Authors:  R G Anderson; M S Brown; J L Goldstein
Journal:  Cell       Date:  1977-03       Impact factor: 41.582

4.  An analysis of the biological properties of monoclonal antibodies against glycoprotein D of herpes simplex virus and identification of amino acid substitutions that confer resistance to neutralization.

Authors:  A C Minson; T C Hodgman; P Digard; D C Hancock; S E Bell; E A Buckmaster
Journal:  J Gen Virol       Date:  1986-06       Impact factor: 3.891

5.  Herpes simplex virus and human cytomegalovirus replication in WI-38 cells. II. An ultrastructural study of viral penetration.

Authors:  J D Smith; E de Harven
Journal:  J Virol       Date:  1974-10       Impact factor: 5.103

6.  Viropexis of herpes simplex virus by HeLa cells.

Authors:  S Dales; H Silverberg
Journal:  Virology       Date:  1969-03       Impact factor: 3.616

7.  Electron microscopy of herpes simplex virus. I. Entry.

Authors:  C Morgan; H M Rose; B Mednis
Journal:  J Virol       Date:  1968-05       Impact factor: 5.103

8.  Comparison of the virion proteins specified by herpes simplex virus types 1 and 2.

Authors:  E N Cassai; M Sarmiento; P G Spear
Journal:  J Virol       Date:  1975-11       Impact factor: 5.103

9.  The properties and sequence of glycoprotein H of herpes simplex virus type 1.

Authors:  U Gompels; A Minson
Journal:  Virology       Date:  1986-09       Impact factor: 3.616

10.  A new mechanism for the neutralization of enveloped viruses by antiviral antibody.

Authors:  S W Gollins; J S Porterfield
Journal:  Nature       Date:  1986 May 15-21       Impact factor: 49.962

View more
  131 in total

1.  Activation of cJUN N-terminal kinase by herpes simplex virus type 1 enhances viral replication.

Authors:  T I McLean; S L Bachenheimer
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

2.  Mutations in herpes simplex virus glycoprotein D distinguish entry of free virus from cell-cell spread.

Authors:  D A Rauch; N Rodriguez; R J Roller
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

3.  Immunization with combined HSV-2 glycoproteins B2 : D2 gene DNAs: protection against lethal intravaginal challenges in mice.

Authors:  Hyung Hoan Lee; Soung Chul Cha; Dong June Jang; Jun Keun Lee; Dong Wan Choo; Young Sik Kim; Hong Sun Uh; Soo Young Kim
Journal:  Virus Genes       Date:  2002-10       Impact factor: 2.332

4.  Characterization of a BHK(TK-) cell clone resistant to postattachment entry by herpes simplex virus types 1 and 2.

Authors:  R J Roller; B C Herold
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

5.  Truncation of herpes simplex virus type 2 glycoprotein B increases its cell surface expression and activity in cell-cell fusion, but these properties are unrelated.

Authors:  Zhenghong Fan; Michael L Grantham; M Shane Smith; Eric S Anderson; James A Cardelli; Martin I Muggeridge
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

6.  Glycoprotein gI of pseudorabies virus promotes cell fusion and virus spread via direct cell-to-cell transmission.

Authors:  L Zsak; F Zuckermann; N Sugg; T Ben-Porat
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

7.  Cellular and viral requirements for rapid endocytic entry of herpes simplex virus.

Authors:  Anthony V Nicola; Stephen E Straus
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

8.  Influence of asparagine-linked oligosaccharides on antigenicity, processing, and cell surface expression of herpes simplex virus type 1 glycoprotein D.

Authors:  D L Sodora; G H Cohen; R J Eisenberg
Journal:  J Virol       Date:  1989-12       Impact factor: 5.103

9.  Characterization of a Marek's disease virus mutant containing a lacZ insertion in the US6 (gD) homologue gene.

Authors:  M S Parcells; A S Anderson; R W Morgan
Journal:  Virus Genes       Date:  1994-09       Impact factor: 2.332

10.  Destabilization of herpes simplex virus type 1 virions by local anesthetics, alkaline pH, and calcium depletion.

Authors:  K Yanagi; S Harada
Journal:  Arch Virol       Date:  1989       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.